312 related articles for article (PubMed ID: 22185963)
1. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study.
Haag-Weber M; Eckardt KU; Hörl WH; Roger SD; Vetter A; Roth K
Clin Nephrol; 2012 Jan; 77(1):8-17. PubMed ID: 22185963
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
Haag-Weber M; Vetter A; Thyroff-Friesinger U;
Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
Weir MR; Pergola PE; Agarwal R; Fink JC; Kopyt NP; Singh AK; Kumar J; Schmitt S; Schaffar G; Rudy A; McKay JP; Kanceva R
Am J Nephrol; 2017; 46(5):364-370. PubMed ID: 29084409
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.
Lissy M; Ode M; Roth K
Drugs R D; 2011; 11(1):61-75. PubMed ID: 21410296
[TBL] [Abstract][Full Text] [Related]
5. Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients.
Azmandian J; Abbasi MR; Pourfarziani V; Nasiri AA; Ossareh S; Ezzatzadegan Jahromi S; Sanadgol H; Amini S; Shahvaroughi Farahani A
Am J Nephrol; 2018; 48(4):251-259. PubMed ID: 30253403
[TBL] [Abstract][Full Text] [Related]
6. Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl.
Hörl WH; Locatelli F; Haag-Weber M; Ode M; Roth K;
Clin Nephrol; 2012 Jul; 78(1):24-32. PubMed ID: 22732334
[TBL] [Abstract][Full Text] [Related]
7. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.
Hahn D; Esezobor CI; Elserafy N; Webster AC; Hodson EM
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011690. PubMed ID: 28066881
[TBL] [Abstract][Full Text] [Related]
8. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R
Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412
[TBL] [Abstract][Full Text] [Related]
9. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.
Gertz B; Kes P; Essaian A; Bias P; Buchner A; Zellner D
Curr Med Res Opin; 2012 Jul; 28(7):1101-10. PubMed ID: 22533679
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients
.
Casadevall N; Dobronravov V; Eckardt KU; Ertürk S; Martynyuk L; Schmitt S; Schaffar G; Rudy A; Krendyukov A; Ode M
Clin Nephrol; 2017 Oct; 88(10):190-197. PubMed ID: 28766493
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
12. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
[TBL] [Abstract][Full Text] [Related]
14. Clinical Comparison of Renogen, a Biosimilar Epoetin-a, with the Originator, Eprex, in Chronic Kidney Disease Anemia in Indonesia: A Preliminary Study.
Hustrini NM; Siregar P; Setiawati A; Nugroho P
Acta Med Indones; 2019 Jul; 51(3):230-237. PubMed ID: 31699946
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar erythropoietin in anemia treatment (BEAT)-Efficacy and safety of a 1:1 dose conversion from EPREX® to EPIAO® in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study.
Miao B; Isachkina AN; Shutov EV; Selyutin AA; Kvitkova LV; Shilo VY; Vetchinnikova ON; Alexandrov IV; Perlin DV; Zuev AV; Davydkin IL; Mironova TP; Solovyova OM; Tutin AP; Omelchenko AM; Vareesangthip K; Khadikova NG; Li M; Li X
Medicine (Baltimore); 2022 Nov; 101(47):e31426. PubMed ID: 36451454
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
[TBL] [Abstract][Full Text] [Related]
17. Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta.
Gertz B; Kohler E; Kes P; Essaian A; Bias P; Buchner A; Elsässer R
Curr Med Res Opin; 2010 Oct; 26(10):2393-402. PubMed ID: 20812790
[TBL] [Abstract][Full Text] [Related]
18. A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-alpha) vs. Eprex® in patients with anaemia of chronic renal failure.
Lim SK; Goh BL; Visvanathan R; Kim SH; Jeon JS; Kim SG; Chang JH; Lim CS; Morad Z
BMC Nephrol; 2021 Nov; 22(1):391. PubMed ID: 34823497
[TBL] [Abstract][Full Text] [Related]
19. Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.
Fishbane S; Singh B; Kumbhat S; Wisemandle WA; Martin NE
Clin J Am Soc Nephrol; 2018 Aug; 13(8):1204-1214. PubMed ID: 29921734
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study
.
London G; Mann J; Goldsmith D; Combe C; Dellanna F; Zaoui P; Hoebel N; Krendyukov A; MacDonald K; Abraham I
Clin Nephrol; 2018 Jan; 89 (2018)(1):1-9. PubMed ID: 29168688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
